Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

Executive Summary

With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy, an FDA decision pending on PCT Therapeutics' ataluren and multiple companies exploring different approaches in preclinical and clinical studies, Scrip provides an overview of the development landscape and commercial results to date.


Related Content

Pfizer’s DMD Setback With Domagrozumab Shifts Focus To Gene Therapy Approach
Finance Watch: Hua Medicine Raises $117.4m While Evaluating A Hong Kong IPO
Patients Can't Clear Translarna's Data Hurdles As PTC Falls Short At FDA Panel
Exondys Revisited? Translarna Brings Efficacy Woes Into US Panel Review
Santhera Shares Sink On Duchenne Setback in Europe
Sarepta Complained To Woodcock About Exondys 51 Review Early And Often
Lucky No. 35? Sarepta And BioMarin Settle Global Patent Disputes
Without J&J, Capricor Plans To Advance Progenitor Cell Therapy In DMD
Duchenne Development: Data Sharing May Enable Trials To Move Beyond Six-Minute Walk
PTC Gambles On Success With Emflaza; Says Price Revision Is Needed


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts